Defined Organism Substance - Pancrelipase

NHPID name:
Pancrelipase

Reference:

Proper name(s):

Common name(s):

Category:
Approved Biological Substance Name
Monograph(s):

Schedule 1:

Source material(s):

Preparations:

Additional details:

Detail:
The only acceptable pharmaceutical dosage forms are delayed-release capsules, tablets, or granules (e.g. enteric-coated tablets, capsules containing enteric-coated granules/(mini)microspheres). The dosage form must be qualified with an additional term to describe the delayed release (e.g. enteric-coated capsules, gastro-resistant tablets, microencapsulated pancreatic enzymes) (WHO 2011).


Roles

Medicinal

Rationale:

Classified as an NHP under Schedule 1, item 2 (an extract) of the Natural Health Products Regulations.

Reference:  NNHPD
Restrictions:

General:

Upper limit:
20000.0

Units:

Detail:
The maximum dose of pancrelipase, in terms of lipase activity, is 20 000 USP units per dosage unit.

Reference:
PDL


Non-NHP

Rationale:

A non-NHP when the product is captured by the Prescription Drug List: When sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency.

Reference:  NNHPD
Date modified: